Objective To investigate the clinical efficacy of Flupentixol and Melitracen combined with Fluoxetine in the treatment of depression after cerebral infarction.Methods 78 cases of depression after cerebral infarction in our hospital from April 2012 to April 2014 were randomly divided into observation group (n=40) and control group (n=38).Control group was treated with Fluoxetine,and observation group was treated with Flupentixol and Melitracen on the basis of control group.Analyzed the clinical effect,HAMD score and NIHSS score in both groups.Results After treatment,the total efficiency of observation group was 92.50％,and that of control group was 73.68％,with statistically significant difference (x 2=4.967,P＜0.05).There were no statistically significant differences in HAMD score and NIHSS score between two groups before treatment (P＞0.05);HAMD score and NIHSS score in both two groups significantly decreased after treatment (P＜0.05),HAMD score and NIHSS score in observation group after treatment were significantly lower than those in control group (P＜0.05).The incidence of adverse events was 27.50％ in observation group,23.68％ in control group,without statistically significant difference between two groups (x 2=0.101,P＞0.05).Conclusion The clinical efficacy of Flupentixol and Melitracen combined with Fluoxetine in the treatment of depression after cerebral infarction is significant,which is helpful to the recovery of depression symptoms and neurological function compared with treatment with Fluoxetine alone,worthy of clinical promotion.%目的 探讨黛力新联合氟西汀对脑梗死后抑郁患者的临床疗效观察.方法 选择2012年4月至2014年4月我院收治的78例脑梗死后抑郁患者,将其随机分为观察组40例、对照组38例,对照组采取氟西汀治疗,观察组在对照组基础上联合运用黛力新治疗,比较两组患者临床疗效、汉密尔顿抑郁量表(HAMD)评分以及神经功能缺损(NIHSS)评分.结果 治疗后总有效率观察组为92.50％,对照组为73.68％,两组比较差异具有统计学意义(x2=4.967,P＜0.05);治疗前两组患者HAMD、NIHSS评分比较差异无统计学意义(P＞0.05),治疗后两组患者HAMD、NIHSS评分均较治疗前显著降低(P＜0.05),且治疗后观察组HAMD、NIHSS评分显著低于对照组(P＜0.05);不良反应发生率观察组为27.50％,对照组为23.68％,两组比较差异无统计学意义(x2=0.101,P＞0.05).结论 黛力新联合氟西汀治疗脑梗死后抑郁症患者具有显著的临床疗效,较单用氟西汀更加有助于患者抑郁症状以及神经功能的恢复,值得临床推广运用.
展开▼
